Wednesday, May 11, 2011

Abbott Labs -Just read 1st quarter global sales amount w/ Humira & almost puked!

Abbott's Humira is currently approved, either as a single therapy or in a combination, to treat rheumatoid and psoriatic arthritis in adults, and a type of juvenile arthritis affecting children. The drug is also approved to treat adults suffering from Crohn's disease, as well as severe chronic plaque psoriasis. Humira is a money spinner for Abbott, with first-quarter global sales improving 17.8 percent to $1.65 billion. Of this, U.S. sales grew 16.2 percent to $630 million.


In another article from RTTNews, Abbott Labs is working on getting Humira approved for Ulcerative Colitis, or UC for short.  The % of people that went into remission isn't very impressive.  It's significant, but barely.


According to the company, of the 248 patients treated with HUMIRA in the study, 16.5 percent achieved clinical remission compared to 9.3 percent on placebo at week 8. At week 52, 17.3 percent achieved clinical remission compared to 8.5 percent on placebo. These results were statistically significant compared to placebo.
HUMIRA is not approved for the treatment of UC. Abbott recently submitted applications to both the U.S. Food and Drug Administration and the European Medicines Agency seeking approval to market HUMIRA for the treatment of moderate to severe UC.

1 comment:

  1. So good topic really i like any post talking about Business Ideas and Advices but i want to say thing to u Business not that only ... you can see in Business Articles2day.Org and more , you shall search in Google and Wikipedia about that Economics .... thanks a gain ,,,

    ReplyDelete